3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
91
Myelodysplastic Syndromes
59
Leukemia
30
Leukemia, Myelomonocytic, Chronic
27
Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Multiple Myeloma
8
Recurrence
7
Lymphoma
7
Primary Myelofibrosis
6
Myeloproliferative Disorders
5
Hematologic Neoplasms
5
Prostatic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm Metastasis
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Erythroblastic, Acute
4
Congenital Abnormalities
4
Breast Neoplasms
4
Anemia, Refractory, with Excess of Blasts
4
Pancreatic Neoplasms
3
Leukemia, Monocytic, Acute
3
Leukemia, Megakaryoblastic, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia, Biphenotypic, Acute
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Renal Insufficiency
2
Interventions
temsirolimus
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pazopanib
1
olaparib
1
eltrombopag
1
cc-486
1
Surveys and Questionnaires
1
Nivolumab
1
Monatide (IMS 3015)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Doxorubicin
1
Docetaxel
1
Diphenhydramine
1
Cytarabine
1
Cyclophosphamide
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pathologic Complete Response
×
Azacitidine
×
Clear all
NCT01757535
2025-07-08
QUAZAR AML-001
Celgene
Phase 3
Completed
472 enrolled
24 charts
1 FDA